{"entity":{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","aka":["BLUESTAR"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT05123482 as recruiting, last updated 2026-09-11. Enrolment is 460 planned participants, an estimate. Interventions: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936). Primary measures include The number of patients with adverse events; The number of patients with serious adverse events. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05123482","url":"https://clinicaltrials.gov/study/NCT05123482"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial","nsclc","sclc"],"sections":[],"technologies":["adc"],"targets":["parp"],"drugs":["puxitatug-samrotecan","rilvegostomig","saruparib","palacaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05123482","phase":"1/2","setting":"A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05123482","source":"https://clinicaltrials.gov/study/NCT05123482","fetchedAt":"2026-10-07T16:53:34.728Z","studySha256":"76577ef198cb97c016f13bc8ab0ea4abe7d8f7a46dbc8c7edad6a91ef6497181","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-11","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":460,"enrolmentType":"ESTIMATED","siteCount":67,"recruitingSiteCount":55,"countries":["Australia","Belgium","Canada","China","Hungary","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","United Kingdom","United States"]}],"started":"2021-10-18","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05123482/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}